View Older Stories
-
FDA approves Moderna's updated 2026-2027 COVID-19 vaccines
-
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
-
Moderna plans $2B convertible notes offering due 2032
-
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
-
Wolfe Research Upgrades Moderna (MRNA) to Peerperform
-
Active options: MRNA SOFI BABA INTC MARA META COIN AMD GOOGL MSFT WMT
-
Moderna (MRNA) call put ratio 1.1 calls to 1 put amid sharp rally
-
Moderna stock pulls back after massive one-day rally: analysts weigh in
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
Moderna (MRNA) call put ratio 1 calls to 2.1 puts amid wide price movement
-
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
-
Morgan Stanley Upgrades Merck (MRK) to Overweight
-
Active options: MRNA AMD AVGO PLTR GOOGL NFLX PFE SOFI NBIS COIN
-
BofA Securities Upgrades Moderna (MRNA) to Neutral
-
Moderna short sellers face $4.8 billion loss amid record stock jump
-
Moderna (MRNA) call put ratio 1 calls to 1.9 puts after INTerpath-001 trial results
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) Following Positive Intismeran Data
-
Stocks expected to have increasing option volume: MRNA RGEN DHR TMO MRVI SKHY
-
Moderna (MRNA) call put ratio 2.1 calls to 1 put into INTerpath-001 trial results
-
William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
-
Moderna shares soar on melanoma drug trial success
-
Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
-
FDA approves Moderna's mRNA influenza vaccine for adults 50 and older
-
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
-
Moderna begins Phase 1 trial of Bundibugyo ebolavirus vaccine
-
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
Moderna (MRNA) Tops Q2 EPS by 6c, Beats on Revenue
-
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
-
Moderna (MRNA) PT Raised to $25 at Wolfe Research
-
Moderna doses first patient in Phase 1 trial for mRNA-4200 cancer therapy
-
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
-
JPMorgan analysts name top short ideas for third quarter 2026
-
Moderna (MRNA) call put ratio 3.5 calls to 1 put with a focus on July 72 and 77 calls as share price down 9.5%
-
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
-
Moderna adds former Biogen CFO Michael McDonnell to its board
-
Moderna Appoints Michael McDonnell to Board of Directors
-
Moderna (MRNA) call put ratio 5 calls to 1 put with a focus on July 10 weekly 80 and 85 calls as share price up 6.5%
-
Moderna (MRNA) call put ratio 6.7 calls to 1 put with a focus on July 2 weekly 68 and 72 calls as share price up 11.5%
-
Moderna (MRNA) PT Raised to $77 at Piper Sandler
-
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
-
Moderna outlines three-horizon growth strategy at 2026 Science Day
-
Moderna outlines mRNA pipeline progress at Science Day event
-
Moderna Science Day Highlights Expanding Potential of mRNA Platform
-
FDA advisory panel votes 9-0 in favor of Moderna's mRNA flu vaccine
-
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
-
Moderna Wins Fda Panel Backing For Mrna Flu Vaccine
-
Moderna to Host Investor Event - Science Day
